OLIE, ITCC-082: A Phase II Trial of Lenvatinib Plus Ifosfamide and Etoposide in Relapsed/Refractory Osteosarcoma
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
While survival rates for patients with relapsed/refractory osteosarcoma are low, kinase inhibitors have shown efficacy in its treatment. The multikinase inhibitor lenvatinib, plus ifosfamide and etoposide, showed antitumor activity in a Phase II study in patients with relapsed/refractory osteosarcoma. This Phase II randomized controlled trial (OLIE) will assess whether the combination of lenvatinib + ifosfamide + etoposide is superior to ifosfamide + etoposide alone in children, adolescents and young adults with relapsed/refractory osteosarcoma. The primary end point is progression-free survival; secondary and exploratory end points include, but are not limited to, overall survival, objective response rate, safety and tolerability, pharmacokinetic characterization of lenvatinib in the combination treatment, quality of life and quantification of baseline unresectable lesions that are converted to resectable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The rationale for combining TKIs with IE, including lenvatinib plus IE, was initially proposed by Gaspar et al.11–13 with the idea of inhibition of angiogenesis may increase uptake of IE into tumor tissue through vascular normalization.”
From Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study (2025) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Isakoff, M. S., Bielack, S. S., Meltzer, P., & Gorlick, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4895 · Cited by 1,567
Comparative analysis of two rates
Miettinen, O., & Nurminen, M. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040211 · Cited by 1,110
Ritter, J., & Bielack, S. S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq276 · Cited by 1,045
Motzer, R. J., Hutson, T. E., Glen, H., Michaelson, M. D., Molina, A., Eisen, T., Jassem, J., Zolnierek, J., Maroto, J. P., Mellado, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00290-9 · Cited by 945
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Casali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy310 · Cited by 617
Self-citation
Research works printed but not linked: 4
- National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines R ). Bone Cancer. Version 1.2021. https://www.nccn.org/professionals/physician gls/pdf /bone.pdf
- Gangireddy M, Nookala V. Ifosfamide. In: StatPearls [Internet] StatPearls Publishing, Trasure Island, FL, USA (2020).
- Eisai Inc. Lenvima (lenvatinib) [prescribing information]. Eisai Inc., Woodcliff Lake, NJ, USA (2020).
- Eisai Inc.. U.S.A. receive priority review from FDA for Lenvima R (lenvatinib) plus Keytruda R (pembrolizumab) applications for advanced renal cell carcinoma and for advanced endometrial carcinoma: applications based on progression-free survival, overall survival, and objective response rate data from respective pivotal phase 3 trials [press release]. Eisai Inc., Tokyo, Japan (2021). https://www.eisai.com/news/2021/news202133.html
Cited by
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma
Gaspar, N., Hung, G.-Y., Strauss, S. J., Campbell-Hewson, Q., Dela Cruz, F. S., Glade Bender, J. L., Koh, K.-N., Whittle, S. B., Chan, G. C.-F., Gerber, N. U., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.4381 · Cited by 28
Self-citationSystemic strategies for osteosarcoma: advances and future directions
Morya, V. K., Magar, A. G., Park, S., & Noh, K.-C. (2025) · Discover Oncology · doi:10.1007/s12672-025-02208-9 · Cited by 32
“For example, a study examining the combination of apatinib with IE found clinically meaningful antitumor activity but emphasized the importance of managing associated toxicities (Table 1) [40].”
van Ewijk, R., Cleirec, M., Herold, N., le Deley, M.-C., van Eijkelenburg, N., Boudou-Rouquette, P., Risbourg, S., Strauss, S. J., Palmerini, E., Boye, K., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102625 · Cited by 19
“[75,95] were not confirmed in the 1:1 randomized phase-II trial comparing lenvatinib + ifosfamide/etoposide to ifosfa-mide/etoposide alone [30,75].”
Self-citationZhang, S., Xing, Z., & Ke, J. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100655 · Cited by 7
“Osteosarcoma is a highly malignant bone tumor primarily affecting adolescents and children, characterized by rapid growth and aggressive invasion [1,2].”
Xie, L., Xu, J., Sun, X., Liu, K., Sun, K., Li, Y., Liu, R., Wang, D., Shao, S., Chen, Z., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65467-8 · Cited by 3
Metadata
- Authors
- Gaspar, N., Campbell-Hewson, Q., Huang, J., Okpara, C. E., & Bautista, F.
- Affiliations
- Institut Gustave Roussy (FR)
- The Great North Children’s Hospital, Royal Victoria Infirmary, Newcastle Upon Tyne, UK
- Eisai (United States) (US)
- Eisai (United Kingdom) (GB)
- Hospital Infantil Universitario Niño Jesús (ES)
- Corresponding author
- Gaspar, Nathalie
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2021-08-12
- Volume
- 17
- Issue
- 32
- Pages
- 4249-4261
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- OpenAlex
- W3190087163
- Cited by
- 9
- References
- 46
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 1 · 2022: 1 · 2021: 1
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Future Oncology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
- Eisai Inc.
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- lenvatinib, ifosfamide, etoposide, multikinase inhibitor, combination chemotherapy, progression-free survival, children, adolescents and young adults, pharmacokinetics, quality of life, resectability
- MeSH terms
- Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Etoposide, Humans, Ifosfamide, Middle Aged, Phenylurea Compounds, Quality of Life, Quinolines, Osteosarcoma, Protein Kinase Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: OLIE, ITCC-082: A Phase II Trial of Lenvatinib Plus Ifosfamide and Etoposide in Relapsed/Refractory Osteosarcoma. https://app.cochat.ai/papers/10.2217/fon-2021-0743
- The paper
- Gaspar, N., Campbell-Hewson, Q., Huang, J., Okpara, C. E., & Bautista, F. (2021). OLIE, ITCC-082: A Phase II Trial of Lenvatinib Plus Ifosfamide and Etoposide in Relapsed/Refractory Osteosarcoma. Future Oncology. https://doi.org/10.2217/fon-2021-0743
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.





